Medicine leads the export of traditional Chinese medicine products by 40%

Business news on February 3 although the final data of 2011 has not been published, the basic situation of the import and export of traditional Chinese medicine has become a foregone conclusion In 2011, affected by the rising cost of raw materials and the tightening of international regulatory policies, China's import and export of traditional Chinese medicine products moved forward in fluctuation, with the year-on-year growth of 38% According to the data from January to November 2011 alone, the export has exceeded 2 billion US dollars, an increase of nearly 40% year on year Meng Dongping, vice president of China Chamber of Commerce for the import and export of medical and health products, announced this at a meeting with the media Medicine led the growth of foreign trade, and the export of traditional Chinese medicine and health care products began to move to the high end According to the specific data provided by the comprehensive Department of China Chamber of Commerce for the import and export of traditional Chinese medicine products, the import and export volume of traditional Chinese medicine products reached 2.745 billion US dollars from January to November 2011, up 37.98% year on year Among them, the export is US $2.098 billion, an increase of 39.84% year on year The export is mainly raw materials such as plant extracts and Chinese herbal pieces, accounting for 81.12% of the total The import is US $647 million, an increase of 32.27% year on year The import of Chinese patent medicine, health care products, Chinese herbal medicine and Chinese herbal pieces and extracts accounts for an average The import of Chinese herbal medicine and Chinese herbal pieces is the fastest growing, up to 98.74% The import of health care products The export growth was good, with a year-on-year growth rate of 74.48% In terms of export market, Japan is the main export market of traditional Chinese medicine products in China Affected by the earthquake at the beginning of the year, the export volume of health care products to Japan fell by nearly 50% in the second quarter However, since the third quarter, there has been a recovery growth, making up the gap of negative growth in the first half of the year The annual export growth to Japan reached 31% Meng Dongping said that on the whole, the trade pattern of traditional Chinese medicine products dominated by China's export remained unchanged "China has the dominant voice The export of traditional Chinese medicine and health care products began to move to the high end " In addition, according to the notice of China Chamber of Commerce for import and export of pharmaceutical and health care products, in 2011, driven by rigid demand, the overall economic benefits of China's pharmaceutical industry increased well, and the total annual output value is expected to reach 1.5 trillion yuan, an increase of 23.3% year on year Relying on the strong industry, from January to November, China's pharmaceutical foreign trade developed rapidly, with the import and export volume of 66.02 billion US dollars, a substantial increase of 39.4% year on year, twice the growth rate of the national foreign trade Among them, the export was US $40.29 billion, up 35.5% year on year; the import was US $25.73 billion, up 46.0% year on year "At present, there is a problem that the cost of traditional Chinese medicine is rising too fast and the price factors affect the change of the export volume of traditional Chinese medicine Meng Dongping told reporters Last year, the export price of traditional Chinese medicine was high before and low after Due to the influence of climate, disaster and some human factors, since the beginning of 2011, the prices of basic raw materials such as Chinese herbal medicine and decoction pieces have continued to rise sharply, which has led to the rising export prices of Chinese herbal medicine, extracts and Chinese patent medicine products In the fourth quarter of this year, the prices of Chinese herbal medicine have been significantly reduced, and the price factor has become the main reason for the change in the export volume of Chinese herbal medicine products At the same time, the export growth of health care products is just the opposite The export volume has grown rapidly, with an increase of 360.75%, and the average export price has dropped by more than 50% The international regulatory measures are increasingly strict, and the foreign trade environment is more severe Meng Dongping believes that at present, "the market potential is large, but the difficulties are also growing." Foreign countries have raised standards and set up many technical barriers or thresholds China is the main one affected " Under the concept of "ensuring public health and safety", in recent years, governments of various countries have continuously improved the quality standard system of pharmaceutical products, successively raised the market access threshold, strengthened the supervision and inspection of overseas manufacturers, and strengthened the monitoring and traceability of upstream products According to China Chamber of Commerce for import and export of medicine and health care products, on May 1, 2011, the European Union "traditional herbal medicine directive" was enforced, and Chinese patent medicines in China need to be registered before they can continue to be sold; in June, the European Union food and Drug Administration issued a new decree, which requires that all western pharmaceutical preparations and their APIs exported to Europe must meet the same standards as the EU GMP, and that export enterprises accept regular or irregular Regular inspection, etc At the same time, the European drug quality management agency (EDQM) has further strengthened the control of imported APIs, extending the scope of supervision to the initial reactants; emerging countries have also gradually increased the entry threshold of imported pharmaceutical products, such as Peru's requirement that imported preparations must meet GMP standards, and Brazil has started to adopt the filing system for the management of medical devices On the whole, the procedures of preparation and inspection are becoming more and more complex for Chinese pharmaceutical enterprises to "go out", and the production conditions and quality standards to be met are endless In addition, it was reported that after the financial crisis, the global pharmaceutical market was weak, the growth of traditional pharmaceutical market was weak, and the trend of international trade protectionism was frequent Chinese pharmaceutical products quickly became the key target of foreign trade relief measures against China In 2011, there were frequent trade remedy cases against China There were more than 10 foreign trade remedy cases against Chinese pharmaceutical products, more than the total cases in 2009 and 2010 Developed countries and China's major competitors are taking trade remedy measures as a means to slow down the pace of Chinese pharmaceutical enterprises to seize the international market In order to help enterprises cope with all this, in 2011, China Chamber of Commerce for the import and export of pharmaceutical and health care products set up a platform for pharmaceutical enterprises, held international promotion meetings, policy analysis meetings, training, etc., so that enterprises could make profits in international trade, reduce losses, and achieve remarkable results Meng Dongping said that in 2012, the chamber of Commerce will continue to make efforts to this end Facing new characteristics, pharmaceutical foreign trade is expected to become a leading industry in economic growth this year In 2011, China's pharmaceutical foreign trade faced new characteristics On the one hand, the export growth to emerging markets such as ASEAN, India, Brazil, Russia and South Africa increased significantly The market increment reached 3.5 billion US dollars, 700 million US dollars higher than the traditional market, and the trend of diversified development of export market was more obvious On the other hand, due to the continuous downturn of the global economy, weak growth of market demand, unpredictable trend of RMB exchange rate and other factors, international orders of overseas purchasers have developed to be small and short-term to reduce trade risks At the same time, affected by natural disasters and domestic inflation, the cost of raw materials, logistics, labor and other factors has increased significantly, and the profits of pharmaceutical foreign trade enterprises have become increasingly meager According to a sample survey conducted by China Chamber of Commerce for the import and export of healthcare products, about 50% of pharmaceutical enterprises have a profit margin of less than 5%, of which 20% have a profit margin of only 1% Profit margin continued to hover at a low level According to the analysis of China Chamber of Commerce for import and export of pharmaceutical and health care products, the trend of China's pharmaceutical foreign trade is closely related to the changes in the world economic situation Under the interaction of multiple factors such as the continuous spread of debt crisis in Europe and the United States, the bleak recovery prospects of major developed economies, the lack of impetus for international market demand, and the increase of export risk due to exchange rate changes, China's pharmaceutical foreign trade development will face many difficulties in 2012 Certainty However, under the guarantee of rigid demand, China's pharmaceutical foreign trade is expected to become one of the few industries leading the economic growth next year, and the annual growth of pharmaceutical industry output value and import and export volume is expected to maintain around 20%, a new record.